Newron Pharmaceuticals Valuation
| NWRN Stock | CHF 8.10 0.22 2.64% |
At this time, the firm appears to be overvalued. Newron Pharmaceuticals secures a last-minute Real Value of ₣7.42 per share. The latest price of the firm is ₣8.1. Our model forecasts the value of Newron Pharmaceuticals from analyzing the firm fundamentals such as Profit Margin of (2.44) %, current valuation of 32.84 M, and Return On Equity of -8.4 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Newron Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Newron Pharmaceuticals is based on 3 months time horizon. Increasing Newron Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Newron stock is determined by what a typical buyer is willing to pay for full or partial control of Newron Pharmaceuticals SpA. Since Newron Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Newron Stock. However, Newron Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.1 | Real 7.42 | Hype 8.32 | Naive 9.14 |
The intrinsic value of Newron Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Newron Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Newron Pharmaceuticals SpA helps investors to forecast how Newron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Newron Pharmaceuticals more accurately as focusing exclusively on Newron Pharmaceuticals' fundamentals will not take into account other important factors: Newron Pharmaceuticals Total Value Analysis
Newron Pharmaceuticals SpA is now anticipated to have takeover price of 32.84 M with market capitalization of 81.91 M, debt of 42.93 M, and cash on hands of 58.99 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Newron Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
32.84 M | 81.91 M | 42.93 M | 58.99 M |
Newron Pharmaceuticals Investor Information
The company recorded a loss per share of 0.85. Newron Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Newron Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Newron Pharmaceuticals SpA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Newron Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Newron Pharmaceuticals has an asset utilization ratio of 11.41 percent. This indicates that the Company is making ₣0.11 for each dollar of assets. An increasing asset utilization means that Newron Pharmaceuticals SpA is more efficient with each dollar of assets it utilizes for everyday operations.Newron Pharmaceuticals Ownership Allocation
Newron Pharmaceuticals maintains a total of 17.85 Million outstanding shares. Newron Pharmaceuticals SpA secures 4.96 % of its outstanding shares held by insiders and 7.28 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Newron Pharmaceuticals Profitability Analysis
The company reported the revenue of 5.76 M. Net Loss for the year was (14.9 M) with profit before overhead, payroll, taxes, and interest of 5.76 M.About Newron Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Newron Pharmaceuticals. We calculate exposure to Newron Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Newron Pharmaceuticals's related companies.Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people.
8 Steps to conduct Newron Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Newron Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Newron Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Newron Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Newron Pharmaceuticals' revenue streams: Identify Newron Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Newron Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Newron Pharmaceuticals' growth potential: Evaluate Newron Pharmaceuticals' management, business model, and growth potential.
- Determine Newron Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Newron Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.